Freenome completes business combination with PCSC, begins trading on Nasdaq as FRNM

1. Business combination closed July 20, 2026; trading commenced July 21, 2026 under symbol "FRNM" on Nasdaq Capital Market
2. PIPE investors purchased 24,000,000 shares at $10.00 per share for $240.0 million gross proceeds
3. 107,446,814 shares of New Freenome Common Stock issued and outstanding as of closing date
4. Roche holds 18,692,767 shares (17.4%) post-closing; RA Capital Management holds 15,367,270 shares (14.3%); Perceptive Life Sciences Master Fund holds 13,314,347 shares (12.4%); Andreessen Horowitz holds 5,571,601 shares (5.2%)
5. Board reduced from nine directors to seven directors effective immediately following merger closing
6. Aaron Elliott appointed Chief Executive Officer; Linh H. Le appointed Chief Financial Officer; Riley Ennis appointed Chief Product Officer; Cheng-Ho Jimmy Lin appointed Chief Scientific Officer
7. Ernst & Young LLP engaged as independent registered public accounting firm; WithumSmith+Brown dismissed as PCSC's prior auditor
8. New Freenome ceased to be a shell company upon closing; PCSC successor issuer retained SEC file number 001-42126 and CIK 0002017526

The business combination transition brings Freenome, a cancer screening company, to public markets with $240 million in committed PIPE capital, positioning it to fund product development, regulatory milestones, and commercialization efforts while maintaining a public equity currency for future capital raises and strategic transactions.

1. Jul 20, 202625-NSE
2. Jul 24, 20268-Kthis filing